Committee Name	Tentative Date of Meeting(s)	Advisory Committee 10-Digit Information Line Code
Molecular and Clinical Genetics Panel	May 6–7, November 11–12	3014510231
Neurological Devices Panel	March 25–26, June 3–4, September 23–24, November 6–7	3014512513
Obstetrics and Gynecology Devices Panel	April 17–18, June 19–20, August 14–15, October 16–17, December 11–12	3014512524
Ophthalmic Devices Panel	February 21–22, May 15–16, September 18–19, November 20–21	3014512396
Orthopedic and Rehabilitation Devices Panel	April 21–22, June 16–17, August 18–19, October 20–21, December 8–9	3014512521
Radiological Devices Panel	April 15–16, August 12, November 4	3014512526
National Mammography Quality Assurance Advisory Committee	October 13–14	3014512397
Technical Electronic Product Radiation Safety Standards Committee	October 8	3014512399
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION		
Food Advisory Committee	July 22, December 2	3014510564
CENTER FOR VETERINARY MEDICINE		
Veterinary Medicine Advisory Committee	March day to be announced	3014512548
National Center for Toxicological Research (NCTR)		
Science Advisory Board to NCTR	August 12–13	3014512559

Dated: January 7, 2008.

Randall W. Lutter,

Deputy Commissioner for Policy.

[FR Doc. E8–567 Filed 1–14–08; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Drug Safety and Risk Management Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Drug Safety and Risk Management Advisory Committee. This meeting was announced in the **Federal Register** of December 11, 2007 (72 FR 70336). The amendment is being made to reflect a change in the *Agenda* portion of the document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Teresa A. Watkins, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, FAX: 301–827–6776, e-mail: *Teresa.Watkins@fda.hhs.gov*, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington DC area), code 3014512535. Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of December 11, 2007, FDA announced that a meeting of the Drug Safety and Risk Management Advisory Committee would be held on February 1, 2008. On page 70336, in the second column, the first paragraph of the *Agenda* portion of document is amended to read as follows:

Agenda: The committee will discuss the efficacy and safety of new drug application (NDA) 22–054, INJECTAFER (ferric carboxymaltose injection), Luitpold Pharmaceuticals Inc., used for the treatment of iron deficiency anemia in postpartum patients or iron deficiency anemia in patients with heavy uterine bleeding.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: January 7, 2008.

Randall W. Lutter,

Deputy Commissioner for Policy.

[FR Doc. E8–490 Filed 1–14–08; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notification of Exception to Competition

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notification of Exception to Competition.

SUMMARY: The Health Resources and Services Administration (HRSA) is issuing a non-competitive program expansion supplement to the National Health Care for the Homeless Council (NHCHC) to provide expanded training and technical assistance to HRSA-funded grantees serving individuals who are homeless.

Authority: This activity is under the authority of the Public Health Service Act, section 330(l).